We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Highly Mutated Oncogene Linked to Five Types of Cancer

By Biotechdaily staff writers
Posted on 24 Mar 2004
Cancer researchers have found that mutations in the PIK3CA lipid kinase gene are characteristic of certain types of cancers and pre-cancerous tissues, a finding that may lead to the development of new diagnostic tests and therapeutic approaches centered on this gene.

Phosphatidylinositol 3-kinases (PI3Ks) are important regulators of signaling pathways that control cell survival, proliferation, adhesion, and movement. More...
Investigators at Johns Hopkins University (Baltimore, MD, USA; www.jhu.edu) sequenced PIK3CA from many types of tumors and other tissues. They found that mutations due to the switching of a single nucleotide were present in 32% of colon cancer samples, 27% of glioblastomas, 25% of gastric cancers, 8% of breast cancers, and 4% of lung cancers. In addition, PIK3CA mutations were found in samples taken from pre-malignant colon tumors. These findings, which suggest that PIK3CA may be one of the most highly mutated oncogenes yet identified in human cancers, were published in the March 11, 2004, online edition of Science.

"These findings open the door to developing specific therapies that may prove useful for the treatment of cancers with mutations in PIK3CA,” explained senior author Dr. Victor Velculescu, assistant professor of oncology at Johns Hopkins University. "This kind of information, gleaned from sequencing a patient's tumor, means drugs could be targeted to just the right molecular pathway at just the right time and potentially be more effective with fewer side effects.”




Related Links:
John Hopkins University

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Electrolyte Analyzer
BKE-B
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.